Earnings History Data for PhaseBio Pharmaceuticals, Inc. (PHAS) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

PhaseBio Pharmaceuticals, Inc.

PhaseBio Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. The company's product consists of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor and PB1046, a once-weekly fusion protein for the treatment of pulmonary arterial hypertension, which are in clinical stage. PhaseBio Pharmaceuticals Inc. is based in Malvern, United States.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
12-08-2022	PM		PHAS	PhaseBio Pharmaceuticals, Inc.	50.64	-0.34	-0.33	-0.60	PhaseBio Pharmaceuticals GAAP EPS of -$0.34 misses by $0.03, revenue of $0.21M misses by $0.29M [8/12/2022 8:41 AM]	1.18	-0.03 (-2.14%)	1.20	-0.01 (-0.83%)	0.50 - 4.10	124,966	220,000	876
PhaseBio Pharmaceuticals GAAP EPS of -$0.34 misses by $0.03, revenue of $0.21M misses by $0.29M [8/12/2022 8:41 AM] PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights [Aug-12-22 08:30AM]
16-05-2022	PM	Before the open (May 16)	PHAS	PhaseBio Pharmaceuticals	49.00	-0.23	-0.67	0.00	PhaseBio Pharmaceuticals GAAP EPS of -$0.23 beats by $0.43 [5/16/2022 6:25 AM]	0.9121	-0.12 (-11.45%)	1.09	0.06 (5.83%)	0.91 - 4.24	862,998	570,000	36,393
PhaseBio to seek FDA approval for clotting agent in 4Q 2022 [5/16/2022 6:50 AM] PhaseBio Pharmaceuticals GAAP EPS of -$0.23 beats by $0.43 [5/16/2022 6:25 AM] PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights [May-16-22 06:00AM] PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab [May-16-22 06:00AM] PhaseBio Pharmaceuticals (PHAS) Reports Q1 Loss, Misses Revenue Estimates [May-16-22 07:15AM]
10-11-2021	AH		PHAS	PhaseBio Pharmaceuticals, Inc.	162.86	-0.66	-0.62	-0.86	PhaseBio Pharmaceuticals EPS misses by $0.05, misses on revenue [11/10/2021 4:44 PM]	3.84	0.39 (11.30%)	3.50	0.05 (1.45%)	2.64 - 5.83	973,953	560,000	1,781
PhaseBio Pharmaceuticals EPS misses by $0.05, misses on revenue [11/10/2021 4:44 PM] PhaseBio Pharmaceuticals (PHAS) Reports Q3 Loss, Lags Revenue Estimates [Nov-10-21 05:15PM] PhaseBio Reports Third-Quarter 2021 Financial Results and Recent Business Highlights [Nov-10-21 04:00PM] PhaseBio Pharmaceuticals to Host Investor Call to Discuss Interim Results from Pivotal REVERSE-IT Phase 3 Trial Presented at the American Heart Association Annual Meeting [Nov-10-21 08:01AM]
12-08-2021	PM		PHAS	Phasebio Pharma	150.00	-0.60	-0.60	0.00	PhaseBio Pharmaceuticals EPS misses by $0.14, beats on revenue [8/12/2021 8:46 AM]	3.29	-0.05 (-1.50%)	3.39	0.05 (1.50%)	2.60 - 5.83	198,309	630,000	4,745
PhaseBio Pharmaceuticals EPS misses by $0.14, beats on revenue [8/12/2021 8:46 AM] PhaseBio Reports Second-Quarter 2021 Financial Results and Recent Business Highlights [Aug-12-21 08:30AM] PhaseBio Pharmaceuticals Achieves Enrollment Milestones Supporting Interim Analysis of REVERSE-IT Global Phase 3 Trial, Enabling Preparation of a BLA submission for Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor [Aug-12-21 08:00AM]
15-03-2021	PM		PHAS	Phasebio Pharma	131.00	-1.03	-0.63	0.00	PhaseBio Pharmaceuticals EPS misses by $0.36 [3/15/2021 9:34 AM]	4.00	-0.34 (-7.83%)	4.45	0.11 (2.53%)	2.60 - 6.85	401,615	314,882	12,928
PhaseBio Pharmaceuticals EPS misses by $0.36 [3/15/2021 9:34 AM] PhaseBio Reports Fourth-Quarter and Full-Year 2020 Financial Results and Recent Business Highlights [Mar-15-21 08:00AM]
12-11-2020	AH	4:00 PM ET (Nov 12)	PHAS	PhaseBio Pharmaceuticals, Inc.	100.06	-0.86	-0.77	-0.40	PhaseBio Pharmaceuticals EPS misses by $0.15 [11/12/2020 4:42 PM]	3.66	-0.01 (-0.20%)	3.65	-0.02 (-0.55%)	2.60 - 8.49	212,688	160,746	101

11-08-2020	AH	4:00 PM ET (Aug 11)	PHAS	PhaseBio Pharmaceuticals, Inc.	116.56	-0.98	-0.50	-0.33	PhaseBio Pharmaceuticals EPS misses by $0.47 [8/11/2020 4:23 PM]	3.99	0.08 (1.96%)	4.00	0.09 (2.30%)	2.60 - 9.82	399,869	537,611	13,809

12-05-2020	AH		PHAS	PhaseBio Pharmaceuticals, Inc.	134.41	-0.52	-0.41	-0.30	PhaseBio Pharmaceuticals EPS misses by $0.11, misses on revenue [5/12/2020 4:25 PM]	4.25	0.22 (5.46%)	4.17	-0.08 (-1.88%)	2.60 - 14.08	148,971	343,144	1,854